8-K: CalciMedica Appoints Stephen Bardin as New CFO, Replacing Interim CFO Dan Geffken

CalciMedica has appointed Stephen Bardin as its new Chief Financial Officer, effective after the filing of the company's Q3 2024 report, replacing interim CFO Dan Geffken.

Summary

• CalciMedica announced the resignation of its interim Chief Financial Officer, Dan Geffken, effective one day after the filing of the company's Q3 2024 report.
• Stephen Bardin has been appointed as the new Chief Financial Officer, principal financial officer, and principal accounting officer, effective the same date as Geffken's resignation.
• Bardin has been a consultant for the company since April 2024 and previously held CFO positions at ATAI Life Sciences and various finance roles at BridgeBio Pharma and Myovant Sciences.
• Bardin's compensation includes an annual base salary of $380,000, a $20,000 signing bonus, and eligibility for a 40% target annual performance bonus.
• He also received a stock option for 100,000 shares and restricted stock units for 40,000 shares, both vesting over time.
• Bardin's offer letter includes severance benefits if terminated without cause or if he resigns for good reason, including nine months of base salary, potential bonus payment, and COBRA premium reimbursement.

Sentiment

Score: 7

Explanation: The document is generally positive due to the appointment of a new CFO with relevant experience, but there is a slight negative sentiment due to the resignation of the interim CFO and the potential for transition risks.

Positives

• The appointment of a new CFO with extensive experience in the biopharmaceutical industry is a positive step for the company.
• Stephen Bardin's previous roles at ATAI Life Sciences, BridgeBio Pharma, and Myovant Sciences suggest he has a strong background in finance and operations.
• The compensation package for the new CFO is competitive and includes incentives tied to performance and long-term value creation.

Negatives

• The resignation of the interim CFO, Dan Geffken, may create a period of transition and potential disruption.
• The company will incur costs associated with the new CFO's compensation package, including salary, bonus, and equity grants.

Risks

• The transition to a new CFO could pose a risk if not managed effectively.
• There is a risk that the new CFO's performance may not meet expectations.
• The company's financial performance could be impacted by the costs associated with the new CFO's compensation package.

Future Outlook

The company will file the full offer letter as an exhibit to the Annual Report on Form 10-K for the year ending December 31, 2024.

Management Comments

• The document does not contain any direct quotes from management, but it details the changes in key personnel.

Industry Context

The appointment of a new CFO is a common occurrence in the biopharmaceutical industry, especially for companies in the clinical stage. The new CFO's experience at other similar companies suggests a strategic move to bring in expertise in financial management and operations.

Comparison to Industry Standards

• The compensation package for the new CFO, including base salary, bonus, and equity grants, is generally in line with industry standards for similar roles in biopharmaceutical companies.
• Stephen Bardin's previous experience at companies like ATAI Life Sciences and BridgeBio Pharma is comparable to the experience of CFOs at other clinical-stage biopharmaceutical companies.
• The vesting schedule for the stock options and RSUs is also typical for executive compensation packages in the industry.

Management Changes

Stakeholder Impact

• Shareholders may view the appointment of a new CFO with relevant experience as a positive development.
• Employees may experience a period of transition with the change in leadership.
• The new CFO's expertise could potentially impact the company's financial strategy and operations.

Next Steps

• The company will file the full offer letter as an exhibit to the Annual Report on Form 10-K for the year ending December 31, 2024.
• The new CFO will assume his role after the filing of the Q3 2024 report.

Key Dates

Keywords

Chief Financial Officer, CFO, executive appointment, biopharmaceutical, finance, stock options, restricted stock units, compensation, severance, CalciMedica